Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Dose Escalation, Phase 1 Study of IXAZOMIB (MLN9708), a Second-Generation Proteasome Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies.

Next Previous
X
Search
Trial Profile

An Open-Label, Dose Escalation, Phase 1 Study of IXAZOMIB (MLN9708), a Second-Generation Proteasome Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ixazomib (Primary)
  • Indications Head and neck cancer; Non-small cell lung cancer; Prostate cancer; Soft tissue sarcoma; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Millennium

    • Most Recent Events

    • 13 Mar 2017 Results (n=755) of pooled analysis of (C16001,C16002,C16003,C16004,C16005,C16007,C16008,C16010,C16013,TB-MC010034) ten studies assessing pharmacokinetic analysis of Ixazomib published in the Clinical Pharmacokinetics.
    • 18 Mar 2015 Results published in the Investigational New Drugs.
    • 22 Jun 2012 Actual patient number is 116 according to ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top